These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11566602)

  • 1. 'Troy-bodies': antibodies as vector proteins for T cell epitopes.
    Lunde E; Rasmussen IB; Eidem JK; Gregers TF; Western KH; Bogen B; Sandlie I
    Biomol Eng; 2001 Oct; 18(3):109-16. PubMed ID: 11566602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Troy-bodies": recombinant antibodies that target T cell epitopes to antigen presenting cells.
    Lund E; Rasmussen IB; Western KH; Eidem JK; Sandlie I; Bogen B
    Int Rev Immunol; 2001 Oct; 20(5):647-73. PubMed ID: 11890617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells.
    Lunde E; Munthe LA; Vabø A; Sandlie I; Bogen B
    Nat Biotechnol; 1999 Jul; 17(7):670-5. PubMed ID: 10404160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses.
    Rasmussen IB; Oynebråten I; Høydahl LS; Flobakk M; Lunde E; Michaelsen TE; Bogen B; Sandlie I
    Protein Eng Des Sel; 2012 Mar; 25(3):89-96. PubMed ID: 22233931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies.
    Lunde E; Western KH; Rasmussen IB; Sandlie I; Bogen B
    J Immunol; 2002 Mar; 168(5):2154-62. PubMed ID: 11859101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.
    Rasmussen IB; Lunde E; Michaelsen TE; Bogen B; Sandlie I
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10296-301. PubMed ID: 11517321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troybodies and pepbodies.
    Lunde E; Lauvrak V; Rasmussen IB; Schjetne KW; Thompson KM; Michaelsen TE; Brekke OH; Sollid LM; Bogen B; Sandlie I
    Biochem Soc Trans; 2002 Aug; 30(4):500-6. PubMed ID: 12196123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of central T cell tolerance: recombinant antibodies deliver peptides for deletion of antigen-specific (CD4+)8+ thymocytes.
    Schjetne KW; Thommesen JE; Fredriksen AB; Lunde E; Sandlie I; Bogen B
    Eur J Immunol; 2005 Nov; 35(11):3142-52. PubMed ID: 16184515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted antigen presentation using crosslinked antibody heteroaggregates.
    Snider DP; Segal DM
    J Immunol; 1987 Sep; 139(5):1609-16. PubMed ID: 2957430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of APC in the selection of immunodominant T cell epitopes.
    Ma C; Whiteley PE; Cameron PM; Freed DC; Pressey A; Chen SL; Garni-Wagner B; Fang C; Zaller DM; Wicker LS; Blum JS
    J Immunol; 1999 Dec; 163(12):6413-23. PubMed ID: 10586031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells.
    Bartnes K; Hannestad K
    Immunology; 2000 Apr; 99(4):510-22. PubMed ID: 10792498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the in vitro presentation of minor lymphocyte stimulating determinants by major histocompatibility complex-encoded immune response genes.
    Ryan JJ; Miner DW; Mond JJ; Finkelman FD; Woody JN
    J Immunol; 1987 Apr; 138(8):2392-401. PubMed ID: 2435797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens.
    Kruisbeek AM; Titus JA; Stephany DA; Gause BL; Longo DL
    J Immunol; 1985 Jun; 134(6):3605-14. PubMed ID: 2580891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes.
    Tunheim G; Schjetne KW; Fredriksen AB; Sandlie I; Bogen B
    J Leukoc Biol; 2005 Mar; 77(3):303-10. PubMed ID: 15576418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced T cell responses to antigenic peptides targeted to B cell surface Ig, Ia, or class I molecules.
    Casten LA; Kaumaya P; Pierce SK
    J Exp Med; 1988 Jul; 168(1):171-80. PubMed ID: 2840479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
    Dang LH; Lien LL; Benacerraf B; Rock KL
    J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells.
    Snider DP; Segal DM
    J Immunol; 1989 Jul; 143(1):59-65. PubMed ID: 2471743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
    Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
    J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.